Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report

Pulmonary angiosarcoma is a rare clinical entity with a poor prognosis and no established therapeutic strategies. We present the first case to our knowledge of metastatic pulmonary angiosarcoma, treated with checkpoint inhibitor immunotherapy, and have an excellent response. Until now, patient has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Quang Tien, Pham, Anh Tuan, Nguyen, Thuy Thi, Nguyen, Tam Thi Thanh, Van Le, Ky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255737/
https://www.ncbi.nlm.nih.gov/pubmed/34248542
http://dx.doi.org/10.1159/000516402
_version_ 1783717969669390336
author Nguyen, Quang Tien
Pham, Anh Tuan
Nguyen, Thuy Thi
Nguyen, Tam Thi Thanh
Van Le, Ky
author_facet Nguyen, Quang Tien
Pham, Anh Tuan
Nguyen, Thuy Thi
Nguyen, Tam Thi Thanh
Van Le, Ky
author_sort Nguyen, Quang Tien
collection PubMed
description Pulmonary angiosarcoma is a rare clinical entity with a poor prognosis and no established therapeutic strategies. We present the first case to our knowledge of metastatic pulmonary angiosarcoma, treated with checkpoint inhibitor immunotherapy, and have an excellent response. Until now, patient has been treated with immunotherapy for 1 year, and his disease is stable and well-tolerated.
format Online
Article
Text
id pubmed-8255737
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-82557372021-07-09 Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report Nguyen, Quang Tien Pham, Anh Tuan Nguyen, Thuy Thi Nguyen, Tam Thi Thanh Van Le, Ky Case Rep Oncol Case Report Pulmonary angiosarcoma is a rare clinical entity with a poor prognosis and no established therapeutic strategies. We present the first case to our knowledge of metastatic pulmonary angiosarcoma, treated with checkpoint inhibitor immunotherapy, and have an excellent response. Until now, patient has been treated with immunotherapy for 1 year, and his disease is stable and well-tolerated. S. Karger AG 2021-06-09 /pmc/articles/PMC8255737/ /pubmed/34248542 http://dx.doi.org/10.1159/000516402 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Nguyen, Quang Tien
Pham, Anh Tuan
Nguyen, Thuy Thi
Nguyen, Tam Thi Thanh
Van Le, Ky
Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title_full Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title_fullStr Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title_full_unstemmed Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title_short Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report
title_sort role of immunotherapy in pulmonary angiosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255737/
https://www.ncbi.nlm.nih.gov/pubmed/34248542
http://dx.doi.org/10.1159/000516402
work_keys_str_mv AT nguyenquangtien roleofimmunotherapyinpulmonaryangiosarcomaacasereport
AT phamanhtuan roleofimmunotherapyinpulmonaryangiosarcomaacasereport
AT nguyenthuythi roleofimmunotherapyinpulmonaryangiosarcomaacasereport
AT nguyentamthithanh roleofimmunotherapyinpulmonaryangiosarcomaacasereport
AT vanleky roleofimmunotherapyinpulmonaryangiosarcomaacasereport

Ejemplares similares